• Recruiting

NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma

Updated: May 25

NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma


APG2575

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma


This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG-2575 in combination with Pd/DRd in patients with relapsed/refractory (RR) multiple myeloma (MM). The study consists of dose escalation and dose expansion phases. The study consists of will start with 2 arms noted below, both arms are independent


Sponsor

Ascentage Pharma Group Inc

 

ClinicalTrials.gov Identifier: NCT04942067


Official Title: A Phase Ib/II Open-Label Study of APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma and Immunoglobin Light Chain Amyloidosis


First Posted: June 28, 2021


Click here for details on ClinicalTrials.gov

 

Drug: APG-2575+ Pd

Drug: APG-2575 + DRd

 

APG 2575

Lisaftoclax (Code C156249)

APG 2575

APG-2575

APG2575

Bcl-2 Inhibitor APG 2575

Lisaftoclax

LISAFTOCLAX

 

Locations

United States, Florida

United States, New York

United States, Ohio


Posts Archive